News headlines about Icon (NASDAQ:ICLR) have trended somewhat positive on Thursday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Icon earned a media sentiment score of 0.04 on Accern’s scale. Accern also gave media stories about the medical research company an impact score of 45.9835542985733 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities research analysts recently issued reports on ICLR shares. Zacks Investment Research raised shares of Icon from a “hold” rating to a “buy” rating and set a $131.00 price target on the stock in a research note on Saturday, September 9th. Bank of America started coverage on shares of Icon in a research note on Monday, September 11th. They set a “buy” rating and a $128.00 price target on the stock. Barclays upped their price target on shares of Icon from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Friday, October 27th. ValuEngine raised shares of Icon from a “hold” rating to a “buy” rating in a research note on Friday, September 1st. Finally, Credit Suisse Group reaffirmed an “outperform” rating and set a $120.00 price target (up previously from $105.00) on shares of Icon in a research note on Monday, October 16th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Icon presently has an average rating of “Buy” and a consensus target price of $121.00.

Icon (NASDAQ:ICLR) traded down $0.35 during trading on Thursday, reaching $113.52. 192,114 shares of the company were exchanged, compared to its average volume of 359,456. The stock has a market capitalization of $6,170.00, a P/E ratio of 21.64, a price-to-earnings-growth ratio of 1.74 and a beta of 0.61. The company has a current ratio of 1.90, a quick ratio of 1.90 and a debt-to-equity ratio of 0.31. Icon has a 52 week low of $73.76 and a 52 week high of $124.48.

Icon (NASDAQ:ICLR) last announced its earnings results on Thursday, October 26th. The medical research company reported $1.35 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Icon had a net margin of 16.37% and a return on equity of 28.42%. The business had revenue of $440.30 million for the quarter, compared to the consensus estimate of $438.09 million. During the same quarter in the prior year, the firm posted $1.19 earnings per share. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. sell-side analysts anticipate that Icon will post 5.37 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Icon (ICLR) Stock Price” was originally posted by Daily Political and is owned by of Daily Political. If you are viewing this story on another publication, it was stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this story can be viewed at https://www.dailypolitical.com/2017/12/14/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-icon-iclr-stock-price.html.

About Icon

ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.

Insider Buying and Selling by Quarter for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.